anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a prospective, single center, Phase II biologic effects study of recombinant interleukin-11 (rhIL-11, Neumega) in subjects hemophilia A, moderate or mild; or with Von Willebrand disease unable to take desmopressin acetate (DDAVP) because they are unresponsive, allergic, or DDAVP is contraindicated. The purpose of the study is to establish the biologic efficacy and safety of rhIL-11 in those not able to take DDAVP. Study subjects will include adults, age \>= 18 years, with hemophilia A, moderate, defined as factor VIII 0.01-0.04 U/ml, or mild, defined as factor VIII \>= 0.05 U/ml; or with VWD defined by low VWF:RCo and /or low VWF:Ag, past bleeding history, and/or family history of VWD. A total of 10-16 subjects will be enrolled in order to assure that 10 complete the study. The specific aims of the study are: 1) to determine the biologic effect of rhIL-11 when given 4 consecutive days; 2) to determine the safety of rhIL-11 when used in subjects with hemophilia A, moderate or mild; or with VWD unresponsive or unable to take DDAVP; and 3) to determine the mechanism of the hemostatic effects of rhIL-11. The biologic efficacy outcomes will be measured by VWD-related coagulation tests (VWF:RCo, FVIII:C, VWF:Ag, closure times) before and after rhIL-11 injection. Safety outcomes will be measured by the number and frequency of adverse events, including fever, headache, fatigue, myalgias, arthralgias, fluid retention, or edema. The mechanism of rhIL-11 hemostatic effect will be measured by VWFmRNA before and after rhIL-11 response. Response to DDAVP following rhIL-11 will also be assessed in those in whom DDAVP is not contraindicated. The study will last up to 1 month per subject, and for 24 months for the entire study.
PURPOSE: An arrhythmia treatment material is provided to maximize elution rate of main components in an acidic region, thereby improving lower bio-availability of salt or dronedaron in fast-state. CONSTITUTION: An arrhythmia treatment material is coprecipitate type dronedaron solid dispersion or solid liquid. The coprecipitate type dronedarone solid dispersion or the solid liquid contains a water soluble polymer and dronedarone or pharmaceutically allowable salt. The solid dispersion contains a water soluble polymer and dronedarone or pharmaceutically allowable salt. The dronedaron and the water soluble polimer are contained at a weight ratio of 1:0.2-1:5. The solid dispersion or the solid liquid additionally contains surfactant. A manufacturing method of the dronedarone contained solid dispersion or the solid liquid comprises the following steps: melting the dronedarone or the salt which is pharmaceutically allowable and the water soluble polymer in an organic solvent; and removing the organic solvent by freeze-drying, figure forming drying, compression drying or spray drying. The organic solvent is acetone, ethyl acetate, methanol, ethanol or isopropyl alcohol. The dronedarone contained solid dispersion or the solid liquid is formed into acida, granule, capsule or tablet.
The device includes specific spray means (Figs. 6 and 7) or has variable support means (See Figs. 2 and 3) for holding spray dispensers of different sizes. A sensor 27 detects every time spray cap button 25, 32 is depressed to release a dose of medicament. Each dose release event is then logged in time to the memory of a microprocessor 40. An algorithm program run by the microprocessor compares the frequency and quantity of the dose release events to specific parameters such as predetermined thresholds or background rates predetermined by a physician for a patient or type of patient. If the frequency and quantity of the logged events deviate from the specific parameters by specified amounts, then the device emits a warning signal to the user that can be audible, or visible such as an LED light or a display message on the panel 13. The device is battery operated 14, has a port 17 (See Fig. 4) for data transmission, and can also be used with other dispensing units such as pill dispensers.
NEW MATERIAL:A low molecular protein having the following properties. Molecular weight, 13,000+ or -1,500; isoelectric point, 4.0+ or -0.3 pH; peak of UV absorption in 0.02M tris-HCl buffer solution added with 0.1M NaCl(7.8 pH), 278nm, the lowest point of the absorption 252 nm; the solution obtained by dissolving 3mg of the protein in 1ml of 0.02M tris-HCl buffer solution (7.8 pH) is colorless and transparent; addition of >=70V/V% of acetone, etc. to the solution causes precipitation; the aqueous solution is weakly acidic; color reactions of peptide bond and amino acid, positive to biuret reaction, Folin-Lawry reaction, etc. USE:A carcinostatic agent. It exhibits direct cytotoxicity to the cultured mouse L-cell in vitro, and exhibits antitumor activity against female mouse affected with A sarcoma in vivo. PROCESS:A substance having immunoactivating activity is administered to a mammal, then an endotoxin originated from Gram-negative bacteria or lectin originated from vegetable is administered thereto to induce and produce the objective low molecular protein.
Title medicament comprises immunisant substances derived from pathogens occuring in intestinal pathology which are prepd. by lysis of a bacterial suspension with an amino acid, esp. glycine followed by filtration and lyophilisation, together with essential elements for reconstituting intestinal flora esp. skimmed milk fermented with an anti-bioresistant microorganism e.g. Lacto bacillus acidophilus and lyophilised. Lysates of E. Coli S5, 57, S12 and 3243 together with Streptococcus group DS19, Staphylococcus Aureus S108, Pseudomonas Pyocyanea S76, Proteus Vulgaris S28 and Enterobacter Aerogenes S118 are used in a predetermined mixt. together with an equal part of fermented milk prods.
Nickel pollution is a recognized factor contributing to lung cancer. Understanding the molecular mechanisms of its carcinogenic effects is crucial for lung cancer prevention and treatment. Our previous research identified the downregulation of a long noncoding RNA, maternally expressed gene 3 (MEG3), as a key factor in transforming human bronchial epithelial cells (HBECs) into malignant cells following nickel exposure. In our study, we found that deletion of MEG3 also reduced the expression of RhoGDIβ. Notably, artificially increasing RhoGDIβ levels counteracted the malignant transformation caused by MEG3 deletion in HBECs. This indicates that the reduction in RhoGDIβ contributes to the transformation of HBECs due to MEG3 deletion. Further exploration revealed that MEG3 downregulation led to enhanced c-Jun activity, which in turn promoted miR-200c transcription. High levels of miR-200c subsequently increased the translation of AUF1 protein, stabilizing SOX2 messenger RNA (mRNA). This stabilization affected the regulation of miR-137, SP-1 protein translation, and the suppression of RhoGDIβ mRNA transcription and protein expression, leading to cell transformation. Our study underscores the co-regulation of RhoGDIβ expression by long noncoding RNA MEG3, multiple microRNAs (miR-200c and miR-137), and RNA-regulated transcription factors (c-Jun, SOX2, and SP1). This intricate network of molecular events sheds light on the nature of lung tumorigenesis. These novel findings pave the way for developing targeted strategies for the prevention and treatment of human lung cancer based on the MEG3/RhoGDIβ pathway.
Administration of oxygen in order to maintain SaO2 between 88% and 95%. Fluid resuscitation if needed with isotonic saline during 3 days.
A multi-user system for creating and maintaining a knowledge base is implemented on a variety of computer systems, including single-user personal computers, networked personal computers, and data communications networks, including the Internet. The system has a graphic user interface which can be easily learned by non-programmers. The knowledge base is displayed as a hierarchical multiplicity of nodes, in which each node is related to one or more superior nodes. Title of text, rules, references, and attributes associated with each node are displayed, and may be modified. Simulation is used to verify the knowledge base once generated. Data may be extracted from the bases in the form of hard-copy books, databases for downloading into Web browsers, and databases for downloading into hand-held computers including a multiplicity of grids, and a multiplicity of branches in the form of a logic tree. The user may choose one of the alternative display formats, and the hierarchy can be displayed in either collapsed view or expanded view. Interference between two or more users accessing the system concurrently is prevented by a locking and authorization subsystem, which also prevents unauthorized access to the environment. The system provides an organization of workflow into a multiplicity of development stages. Each such stage has associated with it an authorization level, developers working on the system concurrently are limited by these levels to access only particular stages and levels of development.
Participants will be asked to perform isometric strengthening exercises in lateral rotation and abduction (see Table 1). In a sitting position (with folded towel between body and arm), participants will place their affected arm by the side with the elbow gently tucked in close to the body, elbow flexed at 90°, and the thumb pointing upwards. The opposite hand (the uninvolved side) will resist the lateral rotation and abduction. They will be asked to push against the uninvolved hand, building up to sub-maximal pressure (approximately 50% to 75% of the maximum possible force; practice during the meeting with the treating physiotherapist using EMG recording) over five seconds.
PURPOSE:To prepare a medicinal compd. which effectively prevents the growth of a human immunodeficiency virus without showing side effect by reacting a specific sulfonamide deriv. of beta-cyclodextrin with a sulfonating agent. CONSTITUTION:A sulfonamide deriv. of beta-cyclodextrin wherein at least one of the seven D-glucose units constituting beta-cyclodextrin has been substd. by a unit of the formula is reacted with a sulfonating agent, and if necessary the reaction product is converted into a salt, giving a polysulfuric ester of the sulfonamide deriv. or a salt of the ester. In the formula, R<1> is alkyl, phenyl, naphthyl, or heterocyclic. The sulfonamide deriv. is a new compd. and prepd. by reacting beta-cyclodextrin with a substd. sulfonic acid halide, separating and purifying the reaction product if necessary, reacting it with ammonia, and sulfonamidating the resulting product by a suitable method.
FIELD: medicine. SUBSTANCE: invention relates to prophylaxis and treatment of arteriosclerosis. Invention proposes administration to mammal effective dose of compound CS-866 that is representative of derivatives of biphenyltetrazole. Method provides effectiveness of treatment and prophylaxis due to multiple component influence on pathogenesis of disease and represents the preparation in choice among the row of angiotensin II antagonists. EFFECT: enhanced effectiveness of treatment and prophylaxis, valuable medicinal properties of agent. 4 tbl
Placebo capsules will be administered orally three days and then every three weeks for 24 weeks. SOX and anti-PD-L1 will be intravenously infused every three weeks for 24 weeks.
INTRODUCTION: Total thyroidectomy (TTx) has been reported to be more challenging in patients with Graves' disease, especially in those who are hyperthyroid at the time of surgery. Our aim was to compare outcomes in patients undergoing TTx for Graves' disease compared to other thyroid diseases at a large academic institution with high-volume fellowship-trained endocrine surgeons.
METHODS: In our retrospective analysis from December 2015 to May 2023, patients undergoing TTx for Graves' disease were compared to those undergoing TTx for all other indications excluding advanced malignancy (poorly differentiated thyroid cancer and concomitant neck dissections). Patient demographics, biochemical values, and postoperative outcomes were compared. A subgroup analysis was performed comparing hyperthyroid to euthyroid patients at the time of surgery.
RESULTS: There were 589 patients who underwent TTx, of which 227 (38.5%) had Graves' disease compared to 362 (61.5%) without. Intraoperatively in Graves' patients, nerve monitoring was used more frequently (65.6% versus 57.1%; P = 0.04) and there was a higher rate of parathyroid autotransplantation (32.0% versus 14.4%; P < 0.01). Postoperatively, transient voice hoarseness occurred less frequently (4.8% versus 13.6%; P < 0.01) and there was no difference in temporary hypocalcemia rates or hematoma rates. In our subgroup analysis, 83 (36%) of Graves' patients were hyperthyroid (thyroid-stimulating hormone < 0.45 and free T4 > 1.64) at the time of surgery and there were no differences in postoperative complications compared to those who were euthyroid.
CONCLUSIONS: At a high-volume endocrine surgery center, TTx for Graves' disease can be performed safely without significant differences in postoperative outcomes. Hyperthyroid patients demonstrated no differences in postoperative outcomes.
Pelvic organ prolapse (POP) has a negative impact on the quality of life of affected women and anterior compartment defects remain the most challenging to repair. It was reported that a women has almost a 1 in 5 risk of needing any kind of POP surgery in her lifetime, with anterior wall repair accounting for 40.6% of all of these. Depending on the structures affected, cystocele can be secondary to defects at: A) Level I vaginal support, provided by the uterosacral and cardinal ligaments or B) Level II vaginal support, mainly provided by the pubocervical fascia. Level II defects can be midline or lateral (paravaginal) depending on whether the fascia is weak at the midline or detached from its lateral attachment to the arcus tendineus fasciae pelvis (ATFP). Clinically, these defects are often combined and/or may be bilateral. Hence, careful assessment and individualized planning of the surgical procedure is essential to optimize cystocele repair outcome.

Several surgical techniques and approaches have been used for cystocele repair. These involve native tissue and the use of mesh implanted transvaginally and / or transabdominally.The mainstay for the vaginal repair of a level I defects is to anchor the uterine cervix or vaginal vault to the sacrospinous or the anterior longitudinal ligaments. However, proper restoration of a level II defect is more complex. Although, a classical anterior colporrhaphy might be suitable to correct an isolated midline weakness in the endopelvic fascia, it is suboptimal, on its own, for the repair an associated lateral defect, which is a common association. Indeed, De Lancey reported that paravaginal defects (PVDs) were diagnosed in 89% of women undergoing surgery for cystocele and stress urinary incontinence.

Although a variety of techniques for paravaginal defect repair (PVDR) have been suggested, several of these are now not feasible in many countries following the FDA's ban on transvaginal mesh manufacture, sale and distribution. Therefore, currently there are attempts to utilize minimally invasive approaches and modern devices in PVDR native tissue repair. Applying this principle, e.g. Capio Suture Capturing Device (Boston Scientific) has been proposed to re-attach the vagina to the ATFP using two to four non-absorbable sutures. However, based on anatomical observation, the ATFP is thin its superior part and thicker inferiorly. This is an issue that might affect the reliability of identifying and ensuring a secure anchorage to the ATFP when solely using a transvaginal route. Recently a novel. Technique of PVDR, called transobturator cystocele repair has been published. However, as the technique was described recently, no follow-up data have been reported to support its practice.

The aim of this randomized controlled trial (RCT) is to compare the novel TOCR and standard anterior colporrhaphy (AR) regarding their safety, efficacy and quality-of-life improvement in a one-year follow-up.
Patients use the password-protected Project Prepare website on a computer, tablet, or phone over 10 weeks to view: videos of the swallowing and trismus exercises, tips and stories from former patients, what to expect each week of treatment, recipes and cooking demonstrations, how to take care of their teeth during treatment, strategies for stress relief, and strategies for dry mouth and nausea. This website is designed to reach underserved populations who do not have ready access to specialized preventive care.
This study evaluated the role of the mesenchymal stem cells derived from adipose tissue (MSCs) in provoked ventricular arrhythmias (VAs) in animals with myocardial infarction (MI). The experimental groups were: sham, subjected to sham surgery and intramyocardial saline injection; MIV, infarcted rats subjected to intramyocardial saline injection; MI + MSCs, infarcted rats subjected to intramyocardial MSCs injection. Injections were performed two days after infarction and the arrhythmogenic inducibility experiment was performed the next day. Only 35% of the MI + MSCs group developed VAs, while the one in the MIV group was 65%. The proportion of nonsustained ventricular tachycardia, sustained tachycardia, and ventricular fibrillation was similar between the infarcted groups, but MSCs animals had shorter duration of nonsustained ventricular tachycardia. However, MSCs increased connexin 43 content in the remote area, even above the levels found in the sham group. MSCs prevented the increase of IL-1β in the different areas of the myocardium. There was higher carbonylation and content of 4-hydroxynonenal (4-HNE, a marker of lipoperoxidation) in the myocardium of infarcted rats, but MSCs attenuated the increase of 4-HNE in the infarcted area. In conclusion, MSCs have a protective effect against the development of arrhythmias, but do not imply a significant benefit for animals that have developed VAs. It is possible to think that the cardioprotection of MSCs involves anti-inflammatory/oxidative actions and improvement in the formation of communicating junctions.Graphical abstract.
This arm receives the pantoprazole 40mg tablet. This medication is taken the night before, 2 hours before surgery, and the night after surgery.
To evaluate how breakthrough rotavirus disease contributes to transmission, we examined the impact of rotavirus vaccination on fecal shedding and duration of illness. We used multivariable linear regression to analyze rotavirus quantity by RT-qPCR and duration among 184 episodes of rotavirus diarrhea positive by ELISA in the PROVIDE study. Vaccinated children had less fecal viral shedding compared to unvaccinated children (mean difference = -0.59 log copies per gram of stool; 95% confidence interval [CI], -.99 to -.19). Duration of illness was on average 0.47 days (95% CI, -.23 to 1.17 days) shorter among vaccinated children. Rotarix vaccination reduces shedding burden among breakthrough cases of rotavirus gastroenteritis. Clinical Trials Registration . NCT01375647.
Ischemic heart diseases are a major global cause of death, and despite timely revascularization, heart failure due to ischemia-hypoxia reperfusion (IH/R) injury remains a concern. The study focused on the role of Early Growth Response 1 (EGR1) in IH/R-induced apoptosis in human cardiomyocytes (CMs). Human induced pluripotent stem cell (hiPSC)-derived CMs were cultured under IH/R conditions, revealing higher EGR1 expression in the IH/R group through quantitative real-time polymerase chain reaction (qRT-PCR) and Western blotting (WB). Immunofluorescence analysis (IFA) showed an increased ratio of cleaved Caspase-3-positive apoptotic cells in the IH/R group. Using siRNA for EGR1 successfully downregulated EGR1, suppressing cleaved Caspase-3-positive apoptotic cell ratio. Bioinformatic analysis indicated that EGR1 is a plausible target of miR-124-3p under IH/R conditions. The miR-124-3p mimic, predicted to antagonize EGR1 mRNA, downregulated EGR1 under IH/R conditions in qRT-PCR and WB, as confirmed by IFA. The suppression of EGR1 by the miR-124-3p mimic subsequently reduced CM apoptosis. The study suggests that treatment with miR-124-3p targeting EGR1 could be a potential novel therapeutic approach for cardioprotection in ischemic heart diseases in the future.
Potassium citrate is a citrate salt of potassium. Its molecular formula is K 3C 6H 5O 7• H 2O, and it has the following chemical structure: 

Potassium citrate, USP is a transparent crystals or white, granular powder. It is freely soluble in water; very slightly soluble in alcohol.

Potassium citrate extended-release tablets, USP are yellowish to tan, oral wax-matrix tablets, and contain 10 mEq (1,080 mg) potassium citrate, USP and 15 mEq (1,620 mg) potassium citrate, USP each. Inactive ingredients include carnauba wax and magnesium stearate. 

FDA approved dissolution specification differs from the USP dissolution specification.
An inhaler article includes a tubular housing defining a holder body extending along a longitudinal axis from a mouthpiece end to a consumable receiving end. The holder body includes an inner tube extending along the longitudinal axis and within the tubular housing from a tube intake end to a tube exhaust end. The tube intake end is proximate the consumable receiving end. The inner tube defines an air flow lumen with two or more air flow apertures extending through a wall of the inner tube. An air blocking feature is positioned in the air flow lumen and between two of the air flow apertures. A vibration inducing element disposed on the inner tube proximate to the tube exhaust end or the tube intake end, the vibration inducing element comprises an aperture through the wall of the inner tube and having a tapered or angled downstream aperture edge.
The standard rehabilitation group will be offered participation in the Good Life with osteoArthritis in Denmark programme (GLA:D). The programme includes supervised team group training twice a week for 8 weeks and an education lecture. The GLA:D programme will be followed by 4 weeks of team group training continuing the exercises from the GLA:D programme.
A pharmaceutical composition in the form of a tablet including a first portion and a second portion, wherein the first portion includes guaifenesin having an immediate release profile and a second drug having a sustained release profile, and wherein the second portion includes guaifenesin having a sustained release profile. The second drug can be in the form of a drug-resin complex. The second drug can be either an anti-tussive or a decongestant. The drug-resin complex includes a drug complexed to an ion exchange resin. The ion exchange resin can be a polystyrene sulfonate resin, polacrilex resin, polacrilin potassium, cholestyramine resin, or a colestyramine resin. The drug-resin complex can be provided with a coating, the coating thickness being selected to obtain the desired release profile. The drug-resin complex can be provided with a coating level of from 5% to 50%. The coating level can be from 10% to 35%.